| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ALKS | Ordinary Shares | Options Exercise | +4.16K | +34.67% | 16.2K | Dec 8, 2023 | Direct | F1 | ||
| transaction | ALKS | Ordinary Shares | Tax liability | -$25.9K | -1K | -6.18% | $25.86 | 15.2K | Dec 8, 2023 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ALKS | Non Qualified Stock Option (Right to Buy) | Other | $2.52K | +112 | +2% | $22.52 | 5.71K | Nov 17, 2023 | Ordinary Shares | 112 | $22.52 | Direct | F2, F3 |
| transaction | ALKS | Non Qualified Stock Option (Right to Buy) | Other | $9.5K | +422 | +2% | $22.52 | 21.5K | Nov 17, 2023 | Ordinary Shares | 422 | $22.52 | Direct | F2, F4 |
| transaction | ALKS | Non Qualified Stock Option (Right to Buy) | Other | $7.13K | +231 | +2% | $30.86 | 11.8K | Nov 17, 2023 | Ordinary Shares | 231 | $30.86 | Direct | F2, F5 |
| transaction | ALKS | Non Qualified Stock Option (Right to Buy) | Other | $7.8K | +254 | +1.99% | $30.72 | 13K | Nov 17, 2023 | Ordinary Shares | 254 | $30.72 | Direct | F2, F6 |
| transaction | ALKS | Restricted Stock Unit Award | Other | +119 | +1.99% | 6.1K | Nov 17, 2023 | Ordinary Shares | 119 | Direct | F1, F2, F7 | |||
| transaction | ALKS | Restricted Stock Unit Award | Other | +163 | +2% | 8.33K | Nov 17, 2023 | Ordinary Shares | 163 | Direct | F1, F2, F8 | |||
| transaction | ALKS | Restricted Stock Unit Award | Options Exercise | -4.16K | -50% | 4.16K | Dec 8, 2023 | Ordinary Shares | 4.16K | Direct | F1, F8 |
| Id | Content |
|---|---|
| F1 | Each restricted stock unit represents a contingent right to receive one ordinary share. |
| F2 | Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. |
| F3 | This award is fully vested in accordance with its terms. |
| F4 | Shares subject to the stock option award vest in three equal annual installments commencing on 12/8/2022. |
| F5 | These options are fully vested in accordance with their terms. |
| F6 | Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. |
| F7 | Shares subject to the restricted stock unit award vest in full on 6/29/2024. |
| F8 | Shares subject to the restricted stock unit award vest in three annual installments commencing on 12/8/2022. |